07/07/2020 | Press release | Distributed by Public on 07/07/2020 01:33
Essen. Evonik is launching a natural food supplement on the German market that contains plant pigments known as anthocyanins from Scandinavian wild berries in particularly high concentrations. In Germany, the product MEDOX® is now available in every pharmacy and through online pharmacies. For the first time, Evonik is marketing a product directly to end consumers through pharmacies.
'We are very pleased that we can now make MEDOX® so easily available to consumers in Germany. Particularly, seniors as well as athletes can benefit from the anthocyanin combination in MEDOX®', says Thomas Riermeier, Head of the Health Care Business Line at Evonik. Previously, the product has already been available via webshop in Norway, Sweden, Finland, Denmark and the UK.
Few other plant ingredients for dietary supplements are as well documented scientifically as anthocyanins: the deep purple plant extracts from dark berries have antioxidative properties, contributing to healthier blood circulation.
'The anthocyanins in MEDOX® are valuable, secondary plant compounds, helping to fight free radicals. They support the health of vessels and veins', says Thomas Hermann, Head of the Pharma & Food Ingredients Product Line at Evonik.
In total, 24 placebo-controlled double-blind studies have so far been completed in Norway, Italy, Australia, China and Germany on the specific combination of 17 different anthocyanins in MEDOX®. MEDOX® was originally developed in Norway 20 years ago, where it has been produced ever since.
Health Care is part of Evonik's Nutrition & Care segment that is strategically aligned with long-term and non-cyclical trends that shape society. These include the aging population, a growing middle class and an increasing awareness for healthy and sustainable nutrition worldwide.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around €2.92 billion in 2019 with about 5,300 employees. It is part of Evonik Operations GmbH.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.